|
|
|
|
Explore challenges and solutions in developing novel AAV capsids, focusing on manufacturing complexity, analytical testing, and regulatory considerations for advancing gene therapy effectiveness.
|
|
|
|
|
The shift toward engineered AAV capsids is expanding therapeutic possibilities while making manufacturability, analytical readiness, immunogenicity, and regulatory strategy integral to vector selection from the earliest stages of development.
|
|
|
|
|
Engineered AAV capsids offer improved targeting and efficiency but introduce manufacturing, analytical, immunogenicity, and regulatory complexities requiring early, integrated development strategies.
|
|
|
|
|
Fragmented, manual data practices slow tech transfer and increase risk; centralized digital CMC systems standardize workflows, improve transparency, and accelerate onboarding while maintaining compliance.
|
|
|
|
|
|
|
Standardized AAV manufacturing platforms accelerate gene therapy development from concept to IND, reducing risk, simplifying processes, and supporting efficient scale-up.
|
|
|
|
|
|
|
